Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

RNXT - RenovoRx Inc


IEX Last Trade
1.04
0.010   0.962%

Share volume: 58,285
Last Updated: Fri 30 Aug 2024 09:58:04 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.03
0.01
0.97%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
1.01%
1 Month
-20.93%
3 Months
-12.82%
6 Months
-36.25%
1 Year
-37.04%
2 Year
-53.03%
Key data
Stock price
$1.04
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.53 - $2.35
52 WEEK CHANGE
-$0.40
MARKET CAP 
24.466 M
YIELD 
N/A
SHARES OUTSTANDING 
23.987 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
BETA 
0.74
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$41,555
AVERAGE 30 VOLUME 
$28,193
Company detail
CEO:
Region: US
Website: renovorx.com
Employees: 13
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

renovorx is a medical device company headquartered in silicon valley, california. we are developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral vascular system. the ability to deliver these materials at high concentration to specific vasculature, safely and without perfusion overlap to other regions, is a central paradigm of our technology. we have received fda clearance for the renovocath™ rc120 and are now introducing our innovative technology to the clinical market. renovorx is a highly motivated team with broad experience and an exciting vision for the future of targeted delivery. we are backed by a broad medical advisory board and a strong board of directors. please contact us at info@renovorx.com to learn more.

Recent news